- Dr. Paul Glare of MSKCC commented in an article published by International Business Times about possible limitations of a new scoring system called the Prognosis in Palliative Care Study (PiPS) predictor model that might be able to inform patients in the final stages of cancer of how much time they have left so they can prepare for their passing.
- Allan Halpern of MSKCC is quoted in a Washington Post article about a quiz from Consumer Reports on skin cancer.
- Jed Wolchok of MSKCC announced the approval by the FDA of vemurafenib for metastatic melanoma.
Category Archives: MSK in the News
MSKCC in the News: July 18 – August 1
- Researchers at MSKCC found that in addition to higher rates of physician-detected melanomas, doctors also are more likely to detect thinner lesions, or cancers in the earliest stages.
- A MSKCC study predicts improved survival in primary mediastinal nonseminomatous germ cell tumors.
- Gregory Riely of MSKCC was quoted in a Reuters article about the potential unreliability of CT scans to measure long tumors.
MSKCC in the News: May 14 – June 10
- MSKCC’s Dr. Dennis Chi was recently interviewed on a WCBS news piece about the successful results of a patient treated with modified radical abdominal trachelectomy for cervical cancer, which successfully preserved her fertility.
- A recent New York Times op-ed entitled, Why Medical School Should Be Free, was co-authored by MSKCC’s Peter B. Bach.
- In a BBC News article covering the annual meeting of the American Society of Clinical Oncology in Chicago, clinicians from MSKCC reported on two separate studies carried out at Sloan-Kettering in which two new drugs had improved survival rates of patients with inoperable melanoma, the deadliest forms of skin cancer.